
David Tougeron/oncologypro.esmo.org
Aug 20, 2025, 08:56
David Tougeron: 15 New FFCD/PRODIGE Trials in Digestive Oncology
David Tougeron, Professor at Poitiers University Hospital, shared a post on LinkedIn:
”This year 2 PHRC K were obtain by FFCD:
- EPITFOX (Marie Muller): TFOX +/- IO (vs FOLFOX) in suqamous cell carcinoma of oesophagus.
- NIMOGREL (Anthony Turpin): FOLFIRI plus Nimotuzumab (vs FOLFIRI) in small bowel adenocarcinoma.
About 15 new FFCD/PRODIGE trials in digestive oncology will start in 2025-2027!”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 20, 2025, 09:23
Aug 20, 2025, 08:56
Aug 20, 2025, 07:10
Aug 19, 2025, 20:14
Aug 19, 2025, 20:05
Aug 19, 2025, 20:04
Aug 19, 2025, 19:53
Aug 19, 2025, 19:47